It's hard to believe someone with that kind of background wrote that blog post. He shows a very superficial understanding of the company and technology. I wonder what he thinks now since the announcement with UQ for the development of in vivo imaging agents considering he is/was the co-founder and CEO of a company working in this space. http://www.imaginab.com/index.php
I was going to make a new thread but I'll just put it here. It's only a few clicks away from looking at Professor Andrew Whittaker's UQ research profile, who was specifically mentioned in the announcement and gave a quote.
Some key phrases / terms from the recent announcement to keep in mind:
"This project should also deliver additional data that confirms the broad applicability of our platform technology in the in vivo space.”
"“There is a growing need for flexible approaches to attaching multiple imaging and targeting moieties to sub-micron particles, including nanoparticles.”
"The technology to be developed in this project aims to improve patient clinical practice by combining several advanced imaging technologies onto a single particle using a simple but innovative approach."
Project 4: Polymer Theranostics: Imaging a Treatment in vivo
Molecular imaging has had a profound influence on modern diagnostics and has helped drive the evolving field of nanomedicine. "Theranostics", the portmanteau of therapy and diagnostics, is one sub-section of nanomedicine and offers the opportunity to monitor the effectiveness of a therapy using molecular imaging techniques - this may be achieved by monitoring drug release from a polymeric carrier, defining tumour boundaries or quantifying necrosis. In this project we will develop biocompatible polymeric devices that target a specific disease state in vivo, and subsequently deliver a therapy to treat that disease using various biological stimuli. The effectiveness of treatment will then be monitored using molecular imaging. This will involve utilising advanced chemistries for both the synthesis of the polymer-drug composites, and subsequent ligation of cell-targeting and imaging moieties. The polymeric architecture will be investigated by techniques such as NMR, GPC-MALLS, DLS, HPLC, UV-VIS etc. The polymeric device will incorporate imaging components for modalities such as magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT) and optical imaging to definitively locate and monitor tumour regression.Responsible scientist: Kris Thurecht and Andrew Whittaker
If it isn't this project specfically, then it is something very similar
ADO Price at posting:
9.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)